Division of Rheumatology
1959 NE Pacific St
Health Science Bldg BB561
Campus Box 356428
Seattle, WA 98195
Keith B. Elkon, M.D.
The Mart Mannik, M.D.-Lucile T. Henderson
Endowed Professor in Rheumatology
Head, Division of Rheumatology
Adjunct Professor of Immunology
750 Republican Street
Seattle, WA 98109
EDUCATION AND TRAINING
CURRENT RESEARCH INTERESTS
Dr. Elkon received his medical degree from the University of Witwatersrand, Johannesburg South Africa in 1974 and membership to the Royal College of Physicians (MRCP) in 1978. He received postdoctoral training at the Hammersmith Hospital, London and at the Weill Medical College of Cornell University, New York. Dr. Elkon was formerly Director of the Graduate Program in Immunology and Professor of Medicine at Cornell. He was appointed as Head, Division of Rheumatology, at UW in August, 2001.
Dr. Elkon studies how dead and dying cells are processed in the body in lupus. In addition, he is investigating how cells grow and cause inflammation in rheumatoid arthritis and scleroderma. Read more about his research here...
Wiedeman A, Santer DM, Yan W, Miescher S, Kaisermann F, Elkon KB. Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after stimulation with immune complexes versus toll like receptor agonists. Arthritis Rheum, Jul 9. doi: 10.1002/art.38082. [Epub ahead of print], 2013. Commentary Arthritis Rheum, same issue and Nature Rev Rheum, September, 2013.
Giltiay NV, Chappell CP, Sun X, Kolhatkar N, Teal T, Wiedeman A, Kim J, Tanaka L, Buechler MB, Hamerman JA, Imanishi-Kari T, Clark EA, Elkon KB. Overexpression of TLR7 promotes cell-intrinsic expansion and autoantibody production by transitional T1 B cells. J Exp Med, in press, 2013.
Sun XZ, Wiedeman A, Agrawal N, Teal TH, Tanaka L, Hudkins KL, Alpers CE, Bolland S, Buechler M, Hamerman JA, Ledbetter JA, Liggitt D, Elkon KB. Increased RNase expression reduces inflammation and prolongs survival in TLR7 transgenic mice. J Immunol, 190:2536-2543, 2013.
Elkon KB, Wiedeman A. Type I IFN system in the development and manifestations of SLE. Current Opinion Rheumatol, 24:499-505, 2012.
Elkon KB, Santer DA. Complement, Interferon and Lupus. Current Opinion Immunol, 24:665-70, 2012.
Elkon KB, Rönnblom L. Cytokines as therapeutic targets in SLE. Nat Reviews Rheumatol, 2010.
Elkon, KB. News and Views. Autoimmunity: apoptotic fats grease transcription. Nature Medicine, 15:1246-8, 2009.
Peng YF, Latchman Y, Elkon KB. Monocytes differentiate into dendritic cells and cross-tolerize T cells through PDL-1, J Immunol, 182: 2777-2785, 2009.
Elkon KB. Cell Survival and Death in Rheumatic Diseases.. In: Kelley’s Textbook of Rheumatology. Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS (eds). W.B. Saunders Company, Philadelphia, 8th edition, pp.379-396, 2009.
Santer DM, Yoshio T, Minota S, Möeller T, Elkon KB. Potent induction of interferon-a and chemokines by autoantibodies in the cerebrospinal fluid of patients with neuropsychiatric lupus. J Immunol, 182:1192-1201. 2009.
Okamoto A, Fujio K, van Rooijen N, Tsuno NH, Takahashi K, Tsurui H, Hirose S, Elkon KB, Yamamoto K. Splenic phagocytes promote responses to nucleosomes in (NZB x NZW) F1 mice. J Immunol, 181:5264-5271, 2008.
Duan H, Fleming J, Pritchard DK, Amon LM, Xue J, Arnett HA, Chen G, Breen P, Buckner JH, Molitor JA, Elkon KB, Schwartz S. Combined analysis of monocyte and lymphocyte mRNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum, 58:1465-1474, 2008.
Martin DM, Zhang K, Kenkel J, Hughes G, Clark E, Davidson A, Elkon KB. Autoimmunity stimulated by adoptively transferred dendritic cells is initiated by both a/b and g/d T-cells but does not require MyD88 signaling. J Immunol, 179: 5819-5828, 2007.
Martin, DA, Elkon, KB. Intracellular mammalian DNA stimulates myeloid dendritic cells to produce Type I interferons independently of MyD88 or TLR9. Arthritis Rheum, 54:951-962., 2006.
Martin, DA and Elkon, KB. 2005. Autoantibodies make a U-turn: the toll hypothesis for autoantibody specificity. J Exp Med 202:1465-1469, 2005.